479413-70-2
479413-70-2 structure
- Name: AUDA
- Chemical Name: 12-(1-adamantylcarbamoylamino)dodecanoic acid
- CAS Number: 479413-70-2
- Molecular Formula: C23H40N2O3
- Molecular Weight: 392.575
- Catalog: Research Areas Inflammation/Immunology
- Create Date: 2017-06-22 13:07:03
- Modify Date: 2024-01-04 13:14:14
-
AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC50s of 18 and 69 nM for the mouse and human sEH, respectively[1]. AUDA has anti-inflammatory activity[2].
| Name | 12-(1-adamantylcarbamoylamino)dodecanoic acid |
|---|---|
| Synonyms |
12-[[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-dodecanoic acid
HMS2204E15 12-[(Adamantan-1-ylcarbamoyl)amino]dodecanoic acid 12-{[(3s,5s,7s)-Adamantan-1-ylcarbamoyl]amino}dodecanoic acid Dodecanoic acid, 12-[[(tricyclo[3.3.1.1]dec-1-ylamino)carbonyl]amino]- 12-(3-adamantan-1-ylureido)dodecanoic acid Urea-based compound,18 12-[(tricyclo[3.3.1.1]dec-1-ylcarbamoyl)amino]dodecanoic acid AUDA |
| Description | AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC50s of 18 and 69 nM for the mouse and human sEH, respectively[1]. AUDA has anti-inflammatory activity[2]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 18 nM (mouse sEH) and 69 nM (human sEH)[1] |
| In Vitro | AUDA (0.3-10 μg/mL; 48 hours) dose-dependently suppresses the proliferation of rat VSMCs exposed to PDGF[2]. AUDA (0.3-10 μg/mL; 30 min) dose-dependently upregulats COX-2 expression[2]. AUDA (10, 50 and 100 μM) augments the migratory ability of HCAECs in a dose-dependent manner[3]. AUDA significantly increases the adhesion ability of HCAECs[3]. Cell Proliferation Assay[2] Cell Line: Vascular smooth muscle cell (VSMC) Concentration: 0.3, 1, 3, 10 μg/mL Incubation Time: 48 hours Result: Dose-dependently suppressed the proliferation of rat VSMCs exposed to PDGF. Western Blot Analysis[2] Cell Line: VSMC Concentration: 1, 3, 10, 30 μg/mL Incubation Time: 30 min Result: Dose-dependently upregulated COX-2 expression. |
| In Vivo | AUDA (i.p.; 10 mg/kg; 14 days) reduces TNF-α, MMP-9 and IL-1β expression levels[3]. Animal Model: Male (wild-type) C57BL/6 mice (age, 4-6 weeks; weight, 18-20 g)[3] Dosage: 10 mg/kg Administration: i.p.; 14 days Result: Reduced TNF-α, MMP-9 and IL-1β expression levels. |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 592.7±19.0 °C at 760 mmHg |
| Molecular Formula | C23H40N2O3 |
| Molecular Weight | 392.575 |
| Flash Point | 312.3±21.5 °C |
| Exact Mass | 392.303894 |
| PSA | 78.43000 |
| LogP | 5.61 |
| Vapour Pressure | 0.0±3.6 mmHg at 25°C |
| Index of Refraction | 1.534 |
| Storage condition | -20℃ |
| RIDADR | NONH for all modes of transport |
|---|
|
~98%
479413-70-2 |
| Literature: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Patent: WO2006/45119 A2, 2006 ; Location in patent: Page/Page column 44; 52 ; WO 2006/045119 A2 |
